---
title: "Expanded Access Services: A Clear 2026 Coverage Guide"
description: "What expanded access program services legitimately cover in 2026, what they never cover, and how to tell a real service from an unapproved offer."
url: "https://savemyfat.com/expanded-access-program-services/"
---

# Expanded Access Program Services: What They Cover and What They Don’t

Table of Contents

- [Oscar Tellez](https://savemyfat.com/oscar-tellez/)
- September 22, 2026
- 10:00 am
- [Clinical Trials](https://savemyfat.com/category/clinical-trials/)

![Printed guide to expanded access program services on a sunlit desk beside a stethoscope and amber vials](https://savemyfat.com/wp-content/uploads/2026/08/expanded-access-program-services.png)Expanded access program services: what they cover and what they don't 2

A search for expanded access help now returns companies offering to manage the process for a fee. Some of that work is real, and none of it produces an investigational product or makes a company hand one over. This guide separates what such services cover from what no service can deliver.

**TLDR Expanded access is a federal route to an investigational drug under an active IND held by a willing sponsor, and only a licensed physician can request it. A support service can research, organize, and coordinate. It cannot file for you, cannot force a company to say yes, and cannot obtain a product a clinic sells for cash. Save My Fat provides no such service, and banking adipose tissue guarantees no eligibility, access, or clinical benefit.**

**Important Disclaimer:** Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for any disease. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.

---

When standard options run out, families look for a way to reach a drug that is still in development. Companies have grown up around that search. Before money changes hands, the question is narrow: what does the fee buy?

The pathway itself is federal, set out in [Subpart I](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-I) of 21 CFR Part 312, titled “Expanded Access to Investigational Drugs for Treatment Use.” Our guide to [expanded access programs](https://savemyfat.com/expanded-access-programs-how-patients-can-legally/) covers the pathway in full.

This route leads to an investigational product under an active IND, not to a product a clinic sells for cash.

## What Expanded Access Services Cover

They cover research, paperwork, and coordination around a request that a licensed physician has to make. FDA’s [patient page](https://www.fda.gov/news-events/expanded-access/expanded-access-information-patients) is direct about who asks: “A licensed physician requests the investigational medical product under the expanded access program for you.”

That leaves a defined lane for a third party: looking for an open clinical trial, identifying the sponsor, locating its published policy, gathering records for the physician’s office. None of that work is clinical.

The [Expanded Access Navigator](https://navigator.reaganudall.org/projects/expanded-access-navigator) is described as a partnership between the Reagan-Udall Foundation for the FDA, patient advocacy organizations, the pharmaceutical industry, and the federal government. Its [company directory](https://navigator.reaganudall.org/company-directory) lists manufacturer policies. It is not an FDA website.

---

## What No Service Can Promise

No service can promise supply, authorization, or access. Two decisions sit outside the control of anyone you hire.

The manufacturer’s agreement comes first, and the manufacturer can refuse. FDA’s [information for patients](https://www.fda.gov/news-events/expanded-access/expanded-access-information-patients) states there is “no law or policy that requires a company to provide access to investigational medical products outside of the clinical trial.” FDA notes that companies may decline for reasons including insufficient supply, and that some use lotteries.

FDA’s own findings are the second gate. Under [312.305(a)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-I/section-312.305), FDA must find a serious or immediately life-threatening disease or condition with no comparable or satisfactory alternative therapy, potential benefit that justifies potential risks, and no interference with clinical investigations. For one patient, [312.310](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-I/section-312.310) adds that FDA must also find the patient cannot obtain the drug under another IND or protocol.

The [Right to Try](https://www.congress.gov/115/plaws/publ176/PLAW-115publ176.pdf) statute does not remove that veto. No liability attaches to a sponsor, manufacturer, prescriber, dispenser, or other entity for a decision not to provide access, and the Act creates no new entitlement.

---

## Where a Legitimate Service Ends and an Unapproved Offer Begins

The difference is the product. A request under this pathway moves toward an investigational drug a sponsor is developing under an active IND. An unapproved offer is a product for sale, with no IND behind it.

Expanded access always requires an IND or a protocol under an existing IND, with manufacturing and preclinical data in the submission. A sponsor must agree to supply the product and grant FDA a right of reference to its IND. A clinic selling an unapproved product for cash satisfies none of that.

FDA’s language for patients is blunt. Its [consumer information](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies) page states: “If you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally.” A guide to [spotting fake clinics](https://savemyfat.com/how-to-spot-fake-stem-cell-clinics-red-flag-fda/) covers the other warning signs.

---

## What a Fee Can and Cannot Be For

Federal cost rules govern the sponsor and the drug, not a third party’s service fee. Under [21 CFR 312.8](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.8), “A sponsor must obtain prior written authorization from FDA to charge for an investigational drug,” and “A sponsor may recover only the direct costs of making its investigational drug available.”

One detail gets missed. The added allowance for monitoring, IND reporting, and administrative costs applies only to intermediate-size populations and treatment INDs, not to individual patient requests under 312.310.

Right to Try does not open a market either. It leaves 312.8(d)(1) in force, so cost recovery there is capped at direct costs. It is not a route to buying an experimental product at market price.

---

## Questions to Ask Before You Pay for Help

Ask questions with verifiable answers, each pointing to a document, a decision, or a named person. No answer can promise access.

First, is there an active IND, and has the sponsor agreed to supply the product? Second, where is the company’s published policy, and what does it say? Third, which licensed physician submits the request, and who is accountable? Fourth, what does the fee cover, and is it separate from the sponsor’s authorized cost recovery?

---

## Where Save My Fat Fits, and Where It Does Not

Save My Fat does not provide expanded access services. It does not file these applications, and it cannot obtain an investigational product for anyone.

What it does is narrower. Save My Fat is a connector that links patients and providers with a United States tissue bank. It does not collect, process, store, or treat tissue, and it is not a clinic, a bank, or a medical practice.

Adipose tissue and anything derived from it stays investigational and is not FDA approved for any disease. FDA’s roster of [approved cellular therapies](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products) lists no adipose-derived product. This science is preliminary and early stage, only a licensed provider can advise an individual, and banking guarantees no eligibility, access, or clinical benefit later.

---

## Frequently Asked Questions

### Can anyone guarantee that the company will supply the product?

No. No law or policy requires a company to provide access outside a clinical trial, and companies may decline for reasons including insufficient supply. FDA permission is not the company’s yes.

### Is there a public way to check a manufacturer’s policy?

Yes. The Reagan-Udall Navigator lists manufacturer policies in its directory. It is a partnership rather than an FDA website, so confirm the current policy with the company.

### Can this pathway get me a stem cell product from a clinic?

No. It leads to an investigational drug under an active IND, and Right to Try requires a completed Phase 1 trial and an active IND, for a drug not approved for any use. FDA’s [consumer alert](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes) states that no regenerative medicine products are approved for orthopedic conditions, neurological disorders, cardiovascular or pulmonary disease, or chronic pain.

---

## Key Takeaways

Expanded access is a federal route to an investigational drug under an active IND held by a willing sponsor. A support service can research, organize, and coordinate around a physician’s request. It cannot submit in place of that physician, cannot compel a company to say yes, and cannot deliver a product sold outside a clinical trial. Federal cost rules cap a sponsor’s charge at direct costs and say nothing about a third party’s fee, so get scope and refund terms in writing. Save My Fat provides none of these services, and banking adipose tissue guarantees no eligibility, access, or clinical benefit.

Save My Fat connects patients and providers with a U.S.-based tissue bank. It is not a tissue bank, a laboratory, a medical practice, or a treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, California, Georgia, and Tennessee governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.

Readers weighing adipose tissue banking for potential future use can review [current pricing](https://savemyfat.com/pricing/) or ask a question through the [contact page](https://savemyfat.com/contact-us/).

---

*Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage.*

*This article is for educational purposes only and does not constitute medical or legal advice. Please consult your own licensed healthcare provider before making any decisions about adipose tissue banking or research participation.*

**About the author:** Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.

**Related guide:** [adipose stem cell trials](https://savemyfat.com/adipose-stem-cell-clinical-trials/).

Follow Save My Fat on Google

Set us as a preferred source and Google will show our latest updates more often in your results.

[PrevPreviousAutologous vs Allogeneic: What the Difference Means for Banked Tissue](https://savemyfat.com/adipose-banking-autologous-vs-allogeneic/)

[NextThe Process for an Expanded Access Program Request, Step by StepNext](https://savemyfat.com/expanded-access-program-request-process/)

Adipose Banking

### [What Happens to the Fat Removed During Liposuction?](https://savemyfat.com/fat-removed-during-liposuction/)

 [Read More »](https://savemyfat.com/fat-removed-during-liposuction/)

Oscar Tellez 11/06/2026 10:00 AM

Bone Marrow

### [Bone Marrow Banking vs Fat Banking: How Collection, Storage and FDA Rules Compare](https://savemyfat.com/bone-marrow-banking-vs-fat-banking/)

 [Read More »](https://savemyfat.com/bone-marrow-banking-vs-fat-banking/)

Oscar Tellez 11/05/2026 10:00 AM

Adipose Banking

### [What Is the Best Stem Cell Bank in the United States? Why No Honest Ranking Exists and What to Compare Instead](https://savemyfat.com/best-stem-cell-bank-how-to-compare/)

 [Read More »](https://savemyfat.com/best-stem-cell-bank-how-to-compare/)

Oscar Tellez 11/04/2026 10:00 AM

Regulation

### [Is Stem Cell Banking Legal in the United States? What FDA Allows and What It Does Not](https://savemyfat.com/stem-cell-banking-legal-status-united-states/)

 [Read More »](https://savemyfat.com/stem-cell-banking-legal-status-united-states/)

Oscar Tellez 11/03/2026 10:00 AM

Adipose Banking

### [Can You Bank Your Fat During Liposuction? What Patients Should Ask Before Surgery](https://savemyfat.com/fat-banking-during-liposuction-patient-guide/)

 [Read More »](https://savemyfat.com/fat-banking-during-liposuction-patient-guide/)

Oscar Tellez 11/02/2026 10:00 AM

Regulation

### [The October 2026 Adipose Banking Digest: Laws, FDA Actions, Standards and Pipeline](https://savemyfat.com/adipose-banking-digest-october-2026/)

 [Read More »](https://savemyfat.com/adipose-banking-digest-october-2026/)

Oscar Tellez 10/30/2026 10:00 AM

```json
[{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/savemyfat.com\/expanded-access-program-services\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/savemyfat.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/savemyfat.com\/our-blog\/","name":"Our Blog"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/savemyfat.com\/category\/clinical-trials\/","name":"Clinical Trials"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/savemyfat.com\/expanded-access-program-services\/","name":"Expanded Access Program Services: What They Cover and What They Don’t"}}]}]},{"@context":"https:\/\/schema.org","@graph":[{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","description":"Oscar Tellez is the Founder of Save My Fat, a company that connects patients and physicians with a U.S. tissue bank for adipose tissue banking, so a person's own tissue can be preserved for potential future use in FDA-regulated pathways. He is not a physician.","url":"https:\/\/savemyfat.com\/oscar-tellez\/","email":"info@savemyfat.com","image":{"@type":"ImageObject","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/05\/Oscar-Headshot-Rounded-1.png","width":"200","height":"200"},"worksFor":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"Save My Fat","url":"https:\/\/savemyfat.com"},"knowsAbout":["Adipose Tissue Banking","Cryopreservation","Regenerative Medicine Regulation","Adipose-Derived Cells","Expanded Access Pathways"],"sameAs":["https:\/\/savemyfat.com\/oscar-tellez\/","https:\/\/www.linkedin.com\/in\/o-tellez\/","https:\/\/www.facebook.com\/savemyfat\/","https:\/\/www.instagram.com\/savemyfat\/"]},{"@type":"Article","@id":"https:\/\/savemyfat.com\/expanded-access-program-services\/#article","headline":"Expanded Access Program Services: What They Cover and What They Don’t","url":"https:\/\/savemyfat.com\/expanded-access-program-services\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/savemyfat.com\/expanded-access-program-services\/"},"datePublished":"2026-09-22T10:00:00-04:00","dateModified":"2026-10-02T11:39:38-04:00","description":"What expanded access program services legitimately cover in 2026, what they never cover, and how to tell a real service from an unapproved offer.","inLanguage":"en-US","articleSection":"Expanded Access Program Services","author":{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","url":"https:\/\/savemyfat.com\/oscar-tellez\/"},"publisher":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"Save My Fat","url":"https:\/\/savemyfat.com"},"image":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/08\/expanded-access-program-services.png"},{"@type":"FAQPage","@id":"https:\/\/savemyfat.com\/expanded-access-program-services\/#faq","inLanguage":"en-US","mainEntity":[{"@type":"Question","name":"Can anyone guarantee that the company will supply the product?","acceptedAnswer":{"@type":"Answer","text":"No. No law or policy requires a company to provide access outside a clinical trial, and companies may decline for reasons including insufficient supply. FDA permission is not the company\u2019s yes."}},{"@type":"Question","name":"Is there a public way to check a manufacturer\u2019s policy?","acceptedAnswer":{"@type":"Answer","text":"Yes. The Reagan-Udall Navigator lists manufacturer policies in its directory. It is a partnership rather than an FDA website, so confirm the current policy with the company."}},{"@type":"Question","name":"Can this pathway get me a stem cell product from a clinic?","acceptedAnswer":{"@type":"Answer","text":"No. It leads to an investigational drug under an active IND, and Right to Try requires a completed Phase 1 trial and an active IND, for a drug not approved for any use. FDA\u2019s consumer alert states that no regenerative medicine products are approved for orthopedic conditions, neurological disorders, cardiovascular or pulmonary disease, or chronic pain."}}]}]},{"@context":"https:\/\/schema.org","@type":"WebPage","@id":"https:\/\/savemyfat.com\/expanded-access-program-services\/#webpage","url":"https:\/\/savemyfat.com\/expanded-access-program-services\/","name":"Expanded Access Services: A Clear 2026 Coverage Guide","speakable":{"@type":"SpeakableSpecification","cssSelector":[".smf-speakable"]}}]
```